On the measurement of real R&D: Divisia price indices for UK business enterprise R&D
Gavin Cameron
Abstract
Gavin Cameron
Abstract
This paper argues that, to measure the quantity of R&D undertaken, it is necessary to deflate R&D spending by a measure of its cost. Based on Divisia weighted averages of proxy price series, price indices are constructed for R&D spending in UK manufacturing in eight sectors and as a whole for 1970–1992. These indices are a better guide to the cost of performing R&D than the GDP deflator, which overstates the rise in real business enterprise R&D in the 1980s, although year-on-year changes are less distorted. Divisia indices are theoretically and empirically better at capturing changes in the cost of R&D than are fixed weighted indices. An investigation of the rapidly rising level of pharmaceutical R&D in the UK concludes that the rise is genuine in that it has not been driven by rapid increases in research salaries.
OpenAlex reports 18 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
This paper argues that, to measure the quantity of R&D undertaken, it is necessary to deflate R&D spending by a measure of its cost. Based on Divisia weighted averages of proxy price series, price indices are constructed for R&D spending in UK manufacturing in eight sectors and as a whole for 1970–1992. These indices are a better guide to the cost of performing R&D than the GDP deflator, which overstates the rise in real business enterprise R&D in the 1980s, although year-on-year changes are less distorted. Divisia indices are theoretically and empirically better at capturing changes in the cost of R&D than are fixed weighted indices. An investigation of the rapidly rising level of pharmaceutical R&D in the UK concludes that the rise is genuine in that it has not been driven by rapid increases in research salaries.
Key concepts: Divisia index, GDP deflator, Proxy (statistics), Economics, Price index, Measure (data warehouse), Econometrics, Real gross domestic product